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Abstract
Background: Chronic lung diseases are the third leading cause of death in the United States due in part to an incomplete
understanding of pathways that govern the progressive tissue remodeling that occurs in these disorders. Adenosine is
elevated in the lungs of animal models and humans with chronic lung disease where it promotes air-space destruction and
fibrosis. Adenosine signaling increases the production of the pro-fibrotic cytokine interleukin-6 (IL-6). Based on these
observations, we hypothesized that IL-6 signaling contributes to tissue destruction and remodeling in a model of chronic
lung disease where adenosine levels are elevated.
Methodology/Principal Findings: We tested this hypothesis by neutralizing or genetically removing IL-6 in adenosine
deaminase (ADA)-deficient mice that develop adenosine dependent pulmonary inflammation and remodeling. Results
demonstrated that both pharmacologic blockade and genetic removal of IL-6 attenuated pulmonary inflammation,
remodeling and fibrosis in this model. The pursuit of mechanisms involved revealed adenosine and IL-6 dependent
activation of STAT-3 in airway epithelial cells.
Conclusions/Significance: These findings demonstrate that adenosine enhances IL-6 signaling pathways to promote
aspects of chronic lung disease. This suggests that blocking IL-6 signaling during chronic stages of disease may provide
benefit in halting remodeling processes such as fibrosis and air-space destruction.
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Introduction
Excessive remodeling and fibrosis are detrimental components
of chronic lung diseases such as asthma, chronic obstructive
pulmonary disease (COPD), and interstitial lung disease [1,2,3].
Although substantial information is available concerning the
biogenesis of these disorders, the mechanisms that promote the
extensive tissue remodeling seen remain enigmatic. Chronic lung
diseases are largely untreatable and are the third leading cause of
death in the United States [4,5]. Thus, identifying signaling
pathways involved in the regulation of progressive pulmonary
remodeling may provide novel therapeutic approaches for these
devastating disorders.
Extracellular adenosine is generated following cellular injury
and promotes tissue protection and repair by enhancing anti-
inflammatory processes and stimulating wound healing [6,7,8].
However, excessive adenosine production in the lung promotes
tissue injury and remodeling and has been hypothesized to engage
amplification pathways that contribute to disease chronicity [9].
Accordingly, adenosine levels are elevated in the lungs of humans
and animal models with chronic lung disease [10,11]. Extracellular
adenosine signals through cell surface G-protein coupled adeno-
sine receptors (A1R, A2AR, A2BR, and A3R) [12], which are also
altered in the lungs of animals [11,13] and patients [14,15] with
chronic lung disease. Recent studies suggest that the A2BRi s
responsible for regulating many of the remodeling activities of
adenosine in these disorders [15,16].
Adenosine regulates the production of the pleiotropic cytokine
IL-6 in numerous cell types through engagement of the A2BR
[15,17]. As an inflammatory and pro-fibrotic cytokine, IL-6 is
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COPD [19] and idiopathic pulmonary fibrosis (IPF) [20,21]. IL-6
signals by binding the membrane bound IL-6Ra, which then
associates with the signal-transducing gp130 protein to facilitate
phosphorylation of the transcription factor STAT-3 [22,23].
Phosphorylated STAT-3 translocates to the nucleus where it
regulates target gene expression. IL-6 mediated activation of
STAT-3 has been implicated in several diseases [24,25,26];
however, little is known about the ability of adenosine to activate
this pathway in the context of chronic lung disease.
The ability of adenosine to promote the production of IL-6
together with the pro-fibrotic features of this cytokine led us to
hypothesize that this pathway contributes to features of chronic
lung disease in environments where adenosine levels are elevated.
The goal of this manuscript was to test this hypothesis using a well
characterized model of adenosine-mediated lung injury, the
adenosine deaminase (ADA)-deficient model [9,16,27,28]. In this
model, elevations in lung adenosine levels promote pulmonary
inflammation, air-space destruction and fibrosis. We examined the
contribution of IL-6 in this model by treating these mice with a
novel IL-6 neutralizing antibody and genetically removing IL-6.
Results demonstrated that IL-6 contributes to the development of
pulmonary inflammation, tissue remodeling and fibrosis in ADA-
deficient mice. The pursuit of mechanisms responsible for IL-6
mediated effects on fibrosis revealed an adenosine and IL-6
dependent activation of STAT-3 in airway epithelial cells.
Together these findings identify a novel pathway for adenosine
mediated amplification of pulmonary inflammation, remodeling
and fibrosis, and highlight novel therapeutic approaches for
treating chronic lung diseases.
Methods
Ethics Statement
Animal care was in accordance with institutional and NIH
guidelines. These studies were reviewed and approved by the
University of Texas Health Science Center at the Houston Animal
Welfare Committee in Houston, Texas, USA. The approved
animal protocol number was HSC-AWC-09-188.
Mice
ADA-deficient mice were generated and genotyped as described
previously [29]. Mice homozygous for the null Ada allele were
designated ADA-deficient (Ada
-/-), while mice heterozygous for the
null Ada allele were designated as ADA competent mice (Ada
+). All
mice were on a mixed 129/C57BL/6J background, and all
phenotypic comparisons were performed among littermates. To
generate Ada/IL-6 double knockout mice (Ada/IL-6
-/-), IL-6
-/-
mice congenic on a C57BL/6J background (Jackson Laboratory,
Bar Harbor, ME, USA) were backcrossed with Ada
-/- mice also
congenic on the C57BL/6J background. Mice were housed in
ventilated cages equipped with microisolator lids and maintained
under strict containment protocols.
ADA Enzyme Therapy
Polyethylene glycol modified ADA (PEG-ADA) was generated
by the covalent modification of purified bovine ADA with
activated polyethylene glycol as described [30]. The ADA-
deficient model of lung disease was run in two manners. One to
assess the impact of reversing adenosine levels, in which mice were
injected with PEG-ADA on postnatal day 18, a stage when lung
disease is established but reversible [27]. In this model mice were
given a single injection of PEG-ADA (5 Units) and endpoints were
monitored 72 hours later. However, this model cannot be used for
the assessment of air-space enlargement, because of defects in
alveolargenesis. Therefore, a second model of delayed adenosine
elevations was used [16]. For this model, Ada
-/- mice were
identified at birth by screening for ADA enzymatic activity in the
blood and were maintained on ADA enzyme therapy from
postnatal day 1 until postnatal day 25. Ada
-/- mice received
intramuscular injections of PEG-ADA on postnatal days 1, 5, 9,
13, and 17 (0.625, 1.25, 2.5, 2.5, and 2.5 Units, respectively) and
intraperitoneal (i.p.) injections on postnatal days 21 and 25 (5
Units each). Mice were sacrificed on day 27 after the last PEG-
ADA injection (postnatal day 43). Ada/IL-6
-/- mice were subjected
to ADA enzyme therapy until postnatal day 25 and sacrificed on
day 27 after treatment (postnatal day 43).
IL-6 Neutralization
IL-6 neutralizing and isotype antibodies were provided by UCB
Celltech Inc. (Slough, UK). Subcutaneous injection with IL-6
antibody (30 mg/kg) or isotype antibody (30 mg/kg) were initiated
on postnatal day 26 and subsequent injections were given on day
31 and 37. Treatment groups included Ada
-/- or Ada
+ mice
receiving an IL-6 antibody, isotype antibody, PBS (vehicle), or no
treatment. All mice were littermates, and both males and females
were included in these experiments.
Bronchoalveolar Lavage (BAL), Cellular Differentials, and
Histology
Mice were anesthetized with avertin. The trachea was
cannulated and the lungs were lavaged four times with 0.3 ml of
PBS (0.95–1 ml lavage fluid recovered). Total cell counts were
determined using a hemocytometer, and aliquots were cytospun
onto microscope slides and stained with Diff-Quick (Dade
Behring) for cellular differentials. After lavage, the lungs were
infused with 10% buffered formalin at 25 cm of H2O pressure and
fixed overnight at 4uC. Fixed lung samples were dehydrated and
embedded in paraffin, and sections (5 mm) were collected on
microscope slides and stained with H&E (Shandon-Lipshaw) or
Masson’s Trichome (EM Science) according to the manufacturer’s
instructions. Adenosine levels were quantified in BAL fluid using
HPLC as described [31].
Immunohistochemistry
Immunohistochemistry was performed on 5 mm sections cut
from formalin-fixed, paraffin-embedded lungs. Sections were
rehydrated through graded ethanols to water, endogenous
peroxidases were quenched with 3% hydrogen peroxide, antigen
retrieval was performed (Dako), and endogenous avidin and biotin
was blocked with a Biotin-Blocking System (Dako). Slides were
incubated with primary antibodies for mouse IL-6 (1:200 dilution,
1 hr room temperature, Abcam), phospho-STAT-3 (1:100 dilu-
tion, 4uC overnight, Abcam), or a-sma (1:1000 dilution, 4uC
overnight, mouse monoclonal, Sigma-Aldrich). All sections were
incubated with ABC Elite Streptavidin reagents and appropriate
secondary antibodies. Sections were developed with 3,39-diami-
nobenzidine (Sigma-Aldrich) and counterstained with methyl
green or hematoxylin. For a-sma staining, slides were processed
with the Mouse on Mouse Kit and the Vector Red Alkaline
Phosphatase Substrate Kit (Vector Laboratories).
Western Blot Analysis
Lungs were homogenized and lysed on ice with protein lysis
buffer (1 M Tris (pH7.4), 1 M NaCl, 1% Triton X-100) freshly
supplemented with 1X protease inhibitor mixture (Roche
Diagnostics). A 50 mg portion of total protein was electrophoresed
IL-6 in Adenosine Mediated Lung Disease
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Immobilon-P polyvinylidene difluoride (Millipore), and Western
blotting was performed. For primary antibody detection, a rabbit
polyclonal anti-mouse was used against phospho-STAT-3 (Abcam
1:500), STAT-3 (Abcam 1:500), and a-actin (Sigma 1:5,000).
Secondary HRP-conjugated antibodies (eBioscience) were applied
for 1 hr at room temperature (for P-STAT-3, STAT-3 in 1:1,000;
and for a-actin in 1:10,000). Signals were detected by chemilu-
minesce (Pierce Chemical).
Collagen Quantification
The Sircol Collagen Assay (Biocolor Assays) was used to
measure soluble collagen in BAL fluid according to the
manufacturer’s instructions.
Mucus Quantification
Treatments with an IL-6 antibody (30 mg/kg) or isotype
antibody (30 mg/kg) were initiated on postnatal day 18. Mice were
sacrificed on day 21 and lung sections were stained with periodic
acid-Schiff (PAS) as described [27]. Mucus index scores were
determined using ImagePro Plus as previously described [27].
Ashcroft Score
H&E-stained lung sections were used to determine the Ashcroft
score as previously described [28,32] on 6 mice per group using 20
fields per section in a blinded manner.
Analysis of mRNA by Quantitative RT-PCR
Mice were anesthetized, and the lungs were rapidly removed
and frozen in liquid nitrogen. Total RNA was isolated from frozen
whole-lung tissue using TRIzol reagent (Invitrogen). RNA samples
were then DNase treated and subjected to quantitative real-time
RT-PCR. The primers, probes, and procedures for real-time RT-
PCR were described previously [16,28,33]. Specific transcript
levels for IL-6, CXCL-1, CCL2, osteopontin (OPN), IL-17,
CXCL-2, TNF-a, TIMP-1, MMP-9, MMP-12, fibronectin, and
a1-procollagen were determined by normalization to 18S rRNA
and presented as mean normalized transcript levels using the
comparative Ct method (2
DDCt) [34].
Immunofluorescence
Sections were rehydrated and fixed with acetone and methanol.
Endogenous fluorescence was quenched with NaBH4. Slides were
incubated with primary antibody to fibronectin (1:400 dilution,
1 hr room temperature, rabbit polyclonal, Sigma-Aldrich) fol-
lowed by secondary antibody (1:1000 dilution, 1 hr room
temperature, donkey anti-rabbit IgG Alexa fluor 555-red,
Invitrogen). Sections were covered with Vectashield anti-fade
medium with DAPI (VectorLabs).
Measurement of Vascular Permeability
Organ vascular permeability was quantified by i.p. administra-
tion of Evans blue dye (0.2 mL of 0.5% in PBS). Four hrs later, the
circulation was perfused with PBS and the heart and lung were
harvested. Organ Evans blue concentrations were quantified after
formamide extraction (55uC overnight) by measuring absorbance
at 610 nm with subtraction of reference absorbance at 450 nm.
Evans blue dye contents were determined by comparison to a
standard curve generated from dye dilutions.
Determination of Alveolar Air-space Size
Alveolar air-space size was determined in pressure infused lungs
by measuring mean chord lengths on H&E-stained lung sections
[27]. Representative images were digitized, and a grid consisting of
53 black lines at 10.5 mm intervals was overlaid on the image. This
line grid was subtracted from the lung images using Image-Pro
Plus image analysis software (version 2.0; MediaCybernetics), and
the resultant lines were measured and averaged to give the mean
chord length of the alveolar air-spaces. The final mean chord
lengths represent averages from 10 nonoverlapping images of each
lung specimen. All quantitative studies were performed blinded
with regard to animal genotype.
In vitro Stimulation of Primary Alveolar Macrophages
Primary alveolar macrophages were isolated from the BAL fluid
of Ada
+ and Ada
-/- mice. BAL fluid was centrifuged at 1,000 rpm
for 10 min and cell pellets were resuspended in cell culture media
(RPMI1640 containing 10% FBS and 10,000 U/ml penicillin/
streptomycin). Total cells were counted using a hemocytometer
and portioned into aliquots of 2.5610
5 cells/dish. Cells were
allowed to adhere for 4 hrs at 37uC, 5% CO2. Cells were rinsed
twice with RPMI1640 without FBS to remove non-adherent
lymphocytes and neutrophils. Cells were then treated with either
media alone, NECA (10 mM; Tocris Bioscience), ATP (100 mM),
and deoxyATP (100 mM). For A2BR antagonism, cells were pre-
incubated with MRS1754 (1 mM; Tocris Bioscience) for 30 min
followed by either treatment with NECA or ATP. After incubation
for 12 hrs at 37uC, 5% CO2, culture supernatants were collected
and IL-6 levels were quantified using a mouse IL-6 ELISA kit (BD
Biosciences).
Statistics
Values are expressed as mean 6SEM. As appropriate, groups
were compared by analysis of variance; follow-up comparisons
between groups were conducted using 2-tailed Student’s t test. A P
value of #0.05 was considered to be significant.
Results
Elevated IL-6 and STAT-3 Activation in the Lungs of Ada
-/-
Mice
Ada
-/- mice accumulate adenosine in their lungs in conjunction
with progressive inflammation, alveolar air-space destruction and
fibrosis [27,28] making them a good model for examining
adenosine-dependent features of chronic lung disease [9]. Previous
studies have shown that IL-6 levels are elevated in the lungs of
Ada
-/- mice [16]; however, it is not known if these increases are
dependent on adenosine elevations. To further characterize IL-6
elevations in association with adenosine elevations in this model,
quantitative RT-PCR on whole-lung RNA extracts (Figure 1A)
and IL-6 protein measurements in BAL fluid (Figure 1B) were
determined at a stage when adenosine elevations, pulmonary
inflammation, air-space destruction and fibrosis were prominent
[16]. Results demonstrated increases in IL-6 transcripts and
protein that were diminished following ADA enzyme replacement
therapy to lower adenosine levels [28] (Figure 1A and 1B).
Immunolocalization revealed alveolar macrophages and bronchial
airway epithelial cells as the major sites of adenosine driven IL-6
production (Figure 1C). Consistent with this, primary macrophag-
es isolated from the lungs of ADA-deficient mice released
substantially more IL-6 in short term culture compared to
macrophages isolated from the lungs of control mice (Figure
S1A). Together, these studies demonstrate adenosine dependent
expression of IL-6 during chronic stages of pulmonary disease in
the ADA-deficient model.
Previous studies have demonstrated that engagement of the
A2BR can promote the release of IL-6 from alveolar macrophages
IL-6 in Adenosine Mediated Lung Disease
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determine if signaling through the A2BR also promotes IL-6 release
from alveolar macrophages from ADA-deficient mice, primary
alveolar macrophages were isolated from the lavage and were
stimulated with the nonselective adenosine receptor agonist NECA.
NECA exposurelead to a significantincrease inIL-6release inshort
term culture and this increase was prevented by pretreatment with
the A2BR antagonist MRS-1754 (Figure S1B). Interestingly, ATP
also promoted the release of IL-6 from alveolar macrophages;
however, this release was also blocked by pretreatment with MRS-
1754 suggesting that it is the breakdown of ATP to adenosine that is
mediating this response as opposed to engagement of P2 receptors.
Treatment with dATP did not increase the release of IL-6.
Together, these results suggest that engagement of the A2BRi s
likelyresponsibleincreasingIL-6releasefrom alveolarmacrophages
in the lungs of ADA-deficient mice.
IL-6 Neutralization Decreases Pulmonary Inflammation in
Ada
-/- Mice
Therapeutic approaches utilizing IL-6 neutralizing antibodies
are currently in use for the treatment of inflammatory and
autoimmune diseases [35]. To begin to assess the effectiveness of
this approach in chronic lung disease, Ada
-/- mice were treated
with IL-6 neutralizing antibodies (Figure S2A). Exposure levels of
the anti-IL-6 antibody used were consistent amongst animals and
reached plasma levels of approximately 300 mg/ml (Figure S2B).
Treatment with IL-6 neutralizing antibodies was associated with
decreased histopathology (Figure 2A). Consistent with this, there
was a significant reduction in inflammatory cells recovered from
the BAL fluid on postnatal day 43 (Figure 2B) with differentials
revealing reduced numbers of macrophages (Figure 2C), lympho-
cytes, eosinophils, and neutrophils (Figure 2D). Interestingly,
treatment with IL-6 neutralizing antibodies also led to slight
reductions in adenosine levels (Figure S3), which may reflect
decreases in inflammation and damage in these mice. These
findings demonstrate that treatment with IL-6 neutralizing
antibodies can attenuate adenosine driven pulmonary inflamma-
tion.
Maintenance of pulmonary vascular barrier function plays an
important role in the regulation of pulmonary inflammation [36]
and the loss of pulmonary barrier function has been associated
with the inflammation seen in Ada
-/- mice [37]. To determine the
Figure 1. IL-6 expression in the lungs of Ada
-/- mice and mice given ADA replacement therapy to lower adenosine levels. IL-6
expression was assessed in lung sections, BAL fluid, and whole lungs from postnatal day 18–20 Ada
+ or Ada
-/- mice, and postnatal day 21 Ada
-/- mice
72 hours after treatment with ADA enzyme therapy (PEG-ADA). (A) IL-6 transcript levels were measured in whole-lung RNA extracts using quantitative
RT-PCR. Data are presented as the percentage of b-actin 6SEM, n$4. (B) IL-6 protein levels were quantified in BAL fluid using ELISA. Values are
presented as pg/mg of protein 6SEM, n$4. (C) Immunohistochemical localization of IL-6 in alveolar macrophages (blue arrows) and bronchial
epithelial cells (red arrows). Images are representative of 4 animals from each group. Scale bars: 10 mm. *, p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/-
vs Ada
-/- 6PEG-ADA.
doi:10.1371/journal.pone.0022667.g001
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function, mice were injected with Evans blue dye 4 hrs before
sacrifice on day 43 and organ levels of dye were quantified. Results
demonstrated significant loss of pulmonary vascular permeability
in the lungs of Ada
-/- mice (Figure S4). Moreover, this loss of
vascular permeability was significantly attenuated following
treatment with IL-6 neutralizing antibodies. These findings suggest
that IL-6 regulates the loss of pulmonary barrier function in the
lungs of Ada
-/- mice.
In further pursuit of mechanisms by which IL-6 neutralization
could impact inflammation in the lungs of Ada
-/- mice we
examined levels of key inflammatory mediators. Results revealed
that the reduced pulmonary inflammation following IL-6 neutral-
ization was associated with reductions in inflammatory mediators
known to be IL-6 targets including CXCL1, MCP-1, OPN, IL-17,
and MIP-2 (Figure 3A-E). In contrast, TNF-a (Figure 3F) and
TGF-b (data not shown) were elevated in the lungs of Ada
-/- mice;
however, their expression was not reduced following IL-6
neutralization. These findings suggest that IL-6 influences the
expression of inflammatory mediators that contribute to inflam-
mation in the lungs of Ada
-/- mice.
Decreased Pulmonary Fibrosis in Ada
-/- Mice Treated With
IL-6 Neutralizing Antibodies
We next sought to determine if treatment with IL-6 neutralizing
antibodies had an effect on the pulmonary fibrosis seen in Ada
-/-
mice [16,28]. Treatment of Ada
-/- mice with IL-6 neutralizing
antibodies resulted in reduced lung collagen production as
determined by decreased a1-procollagen transcripts (Figure 4A).
Similarly, there were decreased levels of soluble collagen in the
lungs of Ada
-/- mice treated with IL-6 neutralizing antibodies
(Figure 4B). In addition, there was decreased production and
deposition of fibronectin following IL-6 neutralization (Figure S5).
Moreover, myofibroblast accumulation in the distal airways was
largely prevented following IL-6 neutralization (Figure 4C), and
overall Ashcroft morphological fibrosis scores were improved
(Figure 4D). Collectively, these findings indicate that treatment
with IL-6 neutralizing antibodies attenuates pulmonary fibrosis in
Ada
-/- mice.
IL-6 Neutralization Inhibits Alveolar Air-space
Enlargement and Mucus Metaplasia in Ada
-/- Mice
Air-space enlargement is another adenosine driven pathological
feature noted in the lungs of Ada
-/- mice [27]. We next investigated
the consequences of IL-6 neutralization on this feature and found
that air-space enlargement was largely prevented following the
treatment with IL-6 neutralizing antibodies (Figure 5A). Ada
-/-
mice exhibit increased expression of tissue inhibitor of metallo-
proteinase-1 (TIMP-1), matrix metalloproteinase (MMP)-9, and
MMP-12 [16]. Examination of these mediators following treat-
ment with IL-6 neutralizing antibodies revealed diminished
expression of TIMP-1 and MMP-9 while MMP-12 levels
remained elevated (Figure 5B-D). These results suggest that IL-6
contributes to emphysema in this model by influencing the
expression of regulators of air-space destruction.
The last adenosine-driven phenotype that we examined was
mucus cell metaplasia [27]. This was done by staining mucus
containing cells in the bronchial airways with PAS and then using
Figure 2. Pulmonary inflammation following the treatment of Ada
-/- mice with IL-6 neutralizing antibodies. Mice were given
subcutaneous injections of anti-IL-6 antibodies (30 mg/kg) as described in the methods. (A) Lungs from postnatal day 43 Ada
+ mice treated with IL-6
antibody (left), treatment with the isotype antibody or vehicle PBS revealed no effect, Ada
-/- mice treated with the isotype antibody (middle) or Anti-
IL-6 (right). Images are representative of 11 animals from each group. Scale bars=200 mm. (B) Total BAL inflammatory cells numbers. Cellular
differentials for (C) macrophages, (D) lymphocytes, eosinophils, and neutrophils. Data are presented as mean cell counts 6SEM, n$11. *, p#0.05 Ada
+
vs Ada
-/- and #,p #0.05 Ada
-/- vs Ada
-/- + Anti-IL-6.
doi:10.1371/journal.pone.0022667.g002
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-/- mice treated with IL-6 neutralizing antibodies. Transcript levels of various pro-
inflammatory cytokines and chemokines were measured in whole-lung RNA extracts from postnatal day 43 mice using quantitative RT-PCR. Shown
are levels of (A) CXCL-1, (B) MCP-1, (C) OPN, (D) IL-17, (E) MIP-2, and (F) TNF-a. Transcripts were measured in parallel with 18S rRNA and values are
presented as mean normalized transcript levels (D
2ct) 6SEM, n$4. *, p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/- vs Ada
-/- + Anti-IL-6.
doi:10.1371/journal.pone.0022667.g003
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Results demonstrated that treatment with IL-6 neutralizing
antibodies attenuated mucus cell metaplasia in the lungs of
Ada
-/- mice (Figure S6).
Ada/IL-6 Double Knockout Mice Exhibit Decreased
Pulmonary Inflammation, Fibrosis and Air-space
Destruction
Our results suggest that treatment of Ada
-/- mice with IL-6
neutralizing antibodies leads to attenuation of many of the
pulmonary phenotypes seen in this model. To gain addition
insight into the role of IL-6 in this model we generated Ada/IL-6
double knockout mice and examined key pulmonary phenotypes
[16,27]. Lung histopathology demonstrated reduced pulmonary
injury in Ada/IL-6 double-knockout mice (Figure 6A) together with
a reduction in pulmonary inflammation, including decreased levels
of macrophages, lymphocytes, eosinophils and neutrophils
(Figure 6B-D). Examination of metrics of pulmonary fibrosis
revealed reduced collagen production (Figure 6E), diminished
myofibroblast accumulation (Figure 6F), and reduced Ashcroft
fibrotic scores (Figure 6G). In addition, alveolar air-space
enlargement, was significantly diminished by the genetic removal
of IL-6 (Figure 7). Collectively, these results demonstrate that
genetic removal of IL-6 in Ada
-/- mice leads to attenuated
pulmonary inflammation, fibrosis and air-space destruction,
further implicating IL-6 signaling in mediating aspects of
adenosine driven chronic lung disease.
Adenosine and IL-6 Mediate STAT-3 Activation in Airway
Epithelial Cells
IL-6 activates transcription in part through a pathway that leads
to the phosphorylation of the transcription factor STAT-3, which
when activated translocates to the nucleus to activate target genes
[23]. To determine if STAT-3 was activated in the lungs of Ada
-/-
mice in an adenosine driven manner we monitored the levels of
phosphorylated STAT-3 (P-STAT-3) using Western blot analysis.
Our results demonstrated increased P-STAT-3 in lung homoge-
nates from Ada
-/- mice, which were diminished following PEG-
ADA treatment to lower adenosine levels (Figure 8A). These
findings suggest that STAT-3 is activated in an adenosine driven
manner in the lungs of Ada
-/- mice. We next examined the
contribution of IL-6 to the activation of STAT-3 in this model by
Figure 4. Attenuation of pulmonary fibrosis following IL-6 neutralization. (A) Decreased collagen production. Whole-lung a1-procollagen
transcript levels were measured in RNA extracts from day 43 lungs using quantitative RT-PCR. Transcripts were measured in parallel with 18S rRNA
and values are presented as mean normalized transcript levels (D
2ct) 6SEM, n=6. (B) Soluble collagen levels were measured using the Sircol assay
and data presented as mean mg collagen/ml BAL fluid 6SEM, n$8. (C) Lung sections were stained with an antibody against a-sma to visualize
myofibroblasts (pink). Images are representative of 6 animals from each group. Scale bars: 100 mm. (D) Ashcroft scores were used as a morphometric
approach to quantify overall fibrosis in the lungs, n=6 per group. *, p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/- vs Ada
-/- + Anti-IL-6.
doi:10.1371/journal.pone.0022667.g004
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neutralizing antibodies or following genetic removal of IL-6.
Results demonstrated a substantial reduction of STAT-3 activa-
tion in the lungs of Ada
-/- mice treated with IL-6 neutralizing
antibodies (Figure 8B) or following the genetic removal of IL-6
(Figure 8C). These results indicate that IL-6 is the dominant
activator of STAT-3 in the lungs of Ada
-/- mice.
Next, we performed immunolocalization experiments in lung
sections to localize STAT-3 activation. We found that alveolar
airway epithelial cells were the major cell type exhibiting nuclear
P-STAT-3 in the lungs of Ada
-/- mice (Figure 8D). Moreover,
evidence of STAT-3 activation in alveolar airway epithelial cells
was dramatically attenuated in Ada
-/- mice treated with IL-6
neutralizing antibodies. Similar results were noted in the lungs of
Ada
-/- mice treated with ADA enzyme therapy to lower adenosine
levels or in Ada/IL-6 double knockout mice (data not shown).
These findings suggest that alveolar airway epithelial cells are a
major target of adenosine and IL-6 mediated STAT-3 activation
in the lungs of Ada
-/- mice.
Discussion
Generation of adenosine following cellular damage is an
important component of the injury response where it plays active
roles in processes that protect cells and tissues, limit inflammation
and promote wound healing [6,8,9]. However, excessive adeno-
sine production and signaling have been implicated in the
amplification of remodeling responses that occur in chronic lung
diseases such as COPD and IPF [9]. The mechanisms by which
adenosine promotes chronic tissue remodeling are not well
understood. In the current study, we show that the pro-fibrotic
mediator IL-6 is produced by alveolar macrophages in the airways
of ADA-deficient mice that develop features of chronic lung
disease in response to elevations in adenosine [27]. Furthermore,
Figure 5. Alveolar air-space enlargement in Ada
-/- mice following treatment with IL-6 neutralizing antibodies. Quantitative analysis of
alveolar air-space size was calculated using Image-Pro analysis software on lung sections collected from mice on postnatal day 43. (A) Alveolar air-
space size presented as mean chord lengths in mm 6SEM, n$11. Alterations in mediators associated with alveolar airway space enlargement.
Transcript levels of TIMP-1 (B), MMP-9 (C), and MMP-12 (E) were measured in whole-lung RNA extracts from postnatal day 43 mice using quantitative
RT-PCR. Transcripts were measured in parallel with 18S rRNA and values are presented as mean normalized transcript levels (D
2ct) 6SEM, n$4.
(*, p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/- vs Ada
-/- + Anti-IL-6.
doi:10.1371/journal.pone.0022667.g005
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22667we demonstrate that pharmacologic inhibition or genetic removal
of IL-6 attenuates pulmonary inflammation, fibrosis and air-space
destruction in this model of adenosine driven lung disease. In
addition, STAT-3 was found to be activated in the lungs of ADA-
deficient mice in conjunction with IL-6 elevations, and blocking
IL-6 signaling led to diminished STAT-3 activation, implicating
this pathway in the regulation of IL-6 induced pathologies in this
model. These findings identify a novel mechanism by which
adenosine can promote amplification pathways that lead to disease
progression. Furthermore, these findings suggest that IL-6
neutralizing antibodies might be useful in the treatment of chronic
lung diseases such as COPD and IPF.
IL-6 production in the lungs of ADA-deficient mice was found
to be abundant in alveolar macrophages and we demonstrated
that antagonism of the A2BR could block IL-6 release from these
cells in vitro. These findings are consistent with observations
that engagement of the A2BR can promote IL-6 production and
release from alveolar macrophages isolated from the lungs of
patients with COPD and IPF [15], and human lung fibroblasts
[17]. Furthermore, these findings are consistent with recent
experiments from our lab demonstrating reduced IL-6 produc-
tion in alveolar macrophages in the lungs of A2BRk n o c k o u t
mice exposed to bleomycin [37]. Collectively, these findings
support the model that elevations in adenosine promote IL-6
production from alveolar macrophages through engagement of
the A2BR in chronic lung disease. However, it is important to
note that different observations have been made regarding
A2BR mediated IL-6 production in acute lung injury models
[38,39,40]. Eckel and colleagues demonstrated that genetic
removal of the A2BR was associated with increased IL-6
production in models of acute lung injury [39]. These
discrepancies may be attributed to secondary effects associated
with enhanced inflammation in acute lung injury models in
which the A2BR has been completely deleted or to differences in
cell types that are present in acute or chronic lung disease
models. Understanding the cellular source and mechanism of
IL-6 production in specific lung disorders will be essential to
deciphering the effects of A2BR based therapies.
Figure 6. Pulmonary phenotypes following genetic removal of IL-6 in Ada
-/- mice. (A) Lungs from postnatal day 43 Ada
+, Ada
-/-, and Ada/IL-
6 double knockout mice. Images are representative of 8 animals from each group. Scale bars: 200 mm. (B) Total cell numbers in BAL fluid were
counted using a hemocytometer. BAL cells were cytospun and stained with Diff-Quick, allowing for quantification of macrophages (C) and
lymphocytes, eosinophils, and neutrophils (D). Data are presented as mean cell counts 6SEM, n$8. (E) Soluble collagen levels were measured using
the Sircol Assay. Data are presented as mean mg collagen/ml BAL fluid 6SEM, n$8. (F) Lung sections were stained with an antibody against a-sma to
visualize myofibroblasts (pink). Images are representative of 6 animals from each group. Scale bars=100 mm. (G) Ashcroft scores were used as a
morphometric approach to quantify overall fibrosis in the lungs, n=6. *, p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/- vs. Ada/IL-6
-/-.
doi:10.1371/journal.pone.0022667.g006
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22667A major finding of this study was that treatment with IL-6
neutralizing antibodies or the genetic removal of IL-6 could
decrease inflammation in the lungs of ADA-deficient mice. This
occurred in conjunction with reduced expression of inflammatory
mediators such as CXCL-1, MCP-1, MIP-2, OPN and IL-17. We
chose to examine these particular mediators because of published
evidence that IL-6 can regulate them in models of lung injury
[21,41,42,43,44]. Thus, reductions in these immunomodulatory
molecules could provide mechanistic insight into the diminished
inflammation seen following IL-6 blockade, placing IL-6 early in a
cascade of events contributing to adenosine-induced lung
inflammation. However, it is important to note that not all of
the mediators examined were completely reduced following IL-6
blockade suggesting their regulation may be more complex. In
addition to the reduction in mediator production, the loss of
barrier function in this model, which was also regulated by IL-6,
could contribute to the effects seen on inflammation. It is difficult
to decipher the contribution of these inflammatory responses to
the remodeling responses seen; however, macrophages and
neutrophils are known to produce mediators that contribute to
both fibrosis [1] and air-space destruction [45,46]. Thus, although
cause and effect cannot be established, our results suggest that
blocking IL-6 signaling during chronic stages of lung disease can
attenuate the production of key effector molecules and the loss of
barrier function, both of which likely impact the remodeling
processes seen.
Results from our study also demonstrate that IL-6 contributes
to pulmonary fibrosis in ADA-deficient mice. These are the first
studies to demonstrate the ability to halt the progression of
fibrosis using IL-6 neutralizing antibodies suggesting IL-6 as a
potential therapeutic target for treating pulmonary disorders
where fibrosis is abundant. In further support of this, IL-6 levels
have been shown to be elevated in various pulmonary disorders
associated with fibrosis, including IPF [47], asthma [48] and
COPD [49]. Moreover, in vitro studies have demonstrated pro-
fibrotic activities of IL-6 on fibroblasts and myofibroblasts
[17,50,51], which are considered major effector cells in
pulmonary fibrosis [1]. In addition, IL-6 deficiency attenuates
fibrosis following intra-tracheal bleomycin exposure [21]. Col-
lectively, these findings support a pro-fibrotic role for IL-6 in
chronic lung disease.
In addition to reduced fibrosis, we found that treatment with
IL-6 neutralizing antibodies or genetic removal of IL-6 decreased
alveolar air-space destruction in ADA-deficient mice. Alveolar
air-space destruction is a feature seen in COPD patients
exhibiting emphysema [45]. Moreover, IL-6 levels are elevated
in patients with COPD [49], where it is thought to influence
inflammatory responses that contribute to pulmonary hyperten-
sion associated with this disorder [52]. Our results suggest that
IL-6 may also play an active role in the regulation of air-space
destruction. This could be due to the regulation of inflammation,
or by influencing levels of proteases or anti-proteases involved in
the regulation of air-space integrity. For example, IL-6 has been
shown to regulate the expression of various MMPs [53] and
inhibitors of MMPs such as TIMP-1 [54]. These mediators are
implicated in emphysema [45,46], and we demonstrate that
treatment with IL-6 neutralizing antibodies is associated with
decreased expression of MMPs and TIMP-1. Additional studies
are needed to identify the specific pathways by which IL-6
influences air-space destruction.
In pursuit of cells that are activated by IL-6, we probed lung
sections from ADA-deficient mice for nuclear phospho-STAT-3
immunolocalization. Surprisingly, we found that the most
abundant STAT-3 activation was found in alveolar airway
epithelial cells. Moreover, this activation was lost upon
treatment with ADA enzyme therapy to lower lung adenosine
levels as well as by genetic or pharmacologic blockade of IL-6,
suggesting that adenosine mediated IL-6 production is the
major pathway responsible for STAT-3 activation in this model.
Injury of airway epithelial cells is thought to play a major role in
the pathogenesis of both COPD and IPF [1,45]. Apoptosis of
airway epithelial cells contributes to the loss of air-space
integrity in COPD [45] and persistent injury of these cells is
thought to contribute to the chronic remodeling and fibrogen-
esis seen in IPF [1]. Thus, activation of STAT-3 in airway
epithelial cells may regulate processes that contribute to distal
airway remodeling in these chronic lung diseases. The
consequences of adenosine and IL-6 driven STAT-3 activation
in airway epithelial cells are currently under investigation;
however, our findings identify this cell type as an important
target of this pathway during chronic stages of disease where
adenosine is elevated. Previous studies have demonstrated
activation of STAT-3 in airway epithelial cells where it was
found to play a protective role in acute lung injury processes by
regulating surfactant production [25,55,56,57]. Thus, the role
of IL-6 signaling may differ between acute and chronic stages of
lung disease. This concept has been observed in other disorders
including the progression of colon cancer, where it has been
proposed that classical IL-6 signaling predominates in acute
stages of disease, while IL-6 trans signaling becomes important
in chronic stages [58]. Understanding the mechanisms and
timing behind the protective and remodeling activities of IL-6
in various lung disorders will be important if IL-6 blocking
strategies are to be pursued for the treatment of these disorders.
In conclusion, our studies demonstrate that IL-6 is an
important mediator of inflammation and remodeling in a chronic
lung disease model driven by adenosine [9,15]. Adenosine and
IL-6 are also elevated in models and humans with chronic lung
disease [9,10,11,59] and we speculate that adenosine elevations in
chronic environments serve to elevate IL-6 levels that in turn
activate inflammatory cascades and promote remodeling pro-
cesses such as fibrosis and air-space destruction. Blocking IL-6
signaling during chronic stages of disease may thus provide
benefit in halting remodeling processes such as fibrosis and air-
space destruction.
Figure 7. Alveolar air-space size in Ada/IL-6 double knockout
mice. Quantitativeanalysisofalveolarair-spacesize wascalculatedusing
Image-Pro analysis software on lung sections collected from mice on
postnatalday43.Dataarepresentedasmeanchordlengths in mm6SEM,
n$8. *, p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/- vs. Ada/IL-6
-/-.
doi:10.1371/journal.pone.0022667.g007
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Figure S1 Enhanced IL-6 release from alveolar macro-
phages is mediated by the A2BR. Primary alveolar macro-
phages were isolated from the lungs of ADA-competent (Ada
+)o r
ADA-deficient mice (Ada
-/-) on postnatal day 18 and placed in
short term culture. (A) IL-6 levels measured in culture media after
12 hrs. Data are presented as mean pg/ml6SEM. n=5.
*, p#0.05 Ada
+ vs Ada
-/- . (B) Cells were stimulated with NECA
(10 mM), ATP (100 mM) or dATP (100 mM) for 12 hrs. For A2BR
antagonism, cells were pretreated for 15 min with MRS-1754
(1 mM) before the addition of agonist. IL-6 levels in media were
Figure 8. STAT-3 activation in the lungs of Ada
-/- mice. STAT-3 activation was measured in whole-lung extracts using western blot analysis with
a phospho-STAT-3 antibody. Total STAT-3 levels were also examined and a-actin levels were used as a loading control. Duplicate mice from each
condition are shown. Phospho-STAT-3 band intensity was quantified using Image J analysis and values are presented as the percentage of a-actin
6SEM, n$4. *, p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/- vs. treatment or genetic alteration. Conditions examined include (A) Ada
+ and Ada
-/- mice
treated with ADA enzyme therapy (PEG-ADA), (B) day 43 Ada
+ and Ada
-/- mice treated with IL-6 neutralizing antibodies, and (C) Ada
+, Ada
-/-, IL-6
-/- and
Ada/IL-6
-/- mice. (D) Immunohistochemical localization of P-STAT-3 in alveolar epithelial cells (blue arrows) of Ada
-/- mice. P-STAT-3 was not detected
in lung sections from Ada
+ mice and Ada
-/- mice treated with Anti-IL-6. Images are representative of 4 animals from each group. Scale bars=100 mm.
doi:10.1371/journal.pone.0022667.g008
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increases 6SEM, n=5. * p#0.01 compared to media alone; #
p#0.01 compared to NECA; ##p#0.05 compared to ATP.
(TIF)
Figure S2 Treatment with IL-6 neutralizing antibodies.
(A) Schematic diagram illustrating experimental design. Ada
+ and
Ada
-/- mice were identified at birth and placed on ADA enzyme
replacement therapy (PEG-ADA) until postnatal day 25. Mice
were treated subcutaneously with an IL-6 neutralizing antibody at
postnatal day 26, 31, and 37. Group controls included: no
treatment and isotype antibody. (B) Pharmacokinetic analysis
revealing IL-6 antibody exposure levels in the plasma. Data are
presented as mean mg/ml IL-6 antibody6SEM, n$11.
(TIF)
Figure S3 Lavage adenosine levels. Adenosine levels were
quantified in 100 ml aliquots of BAL fluid using HPLC. Values are
presented as mean adenosine concentrations (nM) 6SEM.
*, p#0.05 compared to Ada
+.
(TIF)
Figure S4 Vascular barrier function following treat-
ment with IL-6 neutralizing antibodies. Ada
+ and Ada
-/-
mice were treated subcutaneously with IL-6 neutralizing antibod-
ies as described in the methods. On day 43, mice were injected
with Evans blue dye. 4 hrs later, mice were anesthetized, perfused
and lungs and hearts were removed. (A) Whole mounts
demonstrating increased Evans blue tissue uptake in the lungs of
Ada
-/- mice and reduced uptake in Ada
-/- treated with IL-6
neutralizing antibodies (Anti IL-6). Images are representative of 4
mice. (B) Organs were extracted in formamide and dye
concentrations were determined in lungs and hearts. Data are
presented as mean mg/lung 6SEM. n=4. *, p#0.05 Ada
+ vs
Ada
-/- and #,p #0.05 Ada
-/- vs Ada
-/- + Anti-IL-6.
(TIF)
Figure S5 Decreased fibronectin in the lungs of Ada
-/-
mice treated with IL-6 neutralizing antibodies. Analyses
were on postnatal day 43. (A) Whole-lung fibronectin transcript
levels were measured using quantitative RT-PCR. Data are
presented as mean normalized 18S rRNA transcript levels (D
2ct)
6SEM, n$4. *, p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/- vs
Ada
-/- + Anti-IL-6. (B) Decreased fibronectin deposition visualized
by fibronectin immunofluorescence (red) blue represents dapi
stained nuclei. Images are representative of 8 animals from each
group. Scale bars: 200 mm.
(TIF)
Figure S6 Decreased mucus cell metaplasia following
treatment with IL-6 neutralizing antibodies. Ada
+ and
Ada
-/- mice were treated subcutaneously with an IL-6 neutralizing
antibodies as described in the methods. Lung sections from day 43
mice were subjected to periodic acid-Schiff (PAS) staining that
stained mucus pink. (A) Representative views of bronchial airways
from 6 mice in each group. (B) Image Pro software was used to
quantify the degree of periodic acid-Schiff staining in bronchial
epithelial cells and data are presented as a mean Mucus Index
6SEM. n=6; p#0.05 Ada
+ vs Ada
-/- and #,p #0.05 Ada
-/- vs
Ada
-/- + Anti-IL-6.
(TIF)
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